New York A06935 requires Medicaid to cover a wearable medical device for treating glioblastoma and other cancers.

New York A06935 amends the social services law to require Medicaid coverage for a wearable medical device that uses low-intensity, alternating electric fields to treat glioblastoma and other cancers. The coverage is based on medical and scientific evidence, including FDA approvals, Medicare coverage determinations, and clinical practice guidelines from organizations like the National Comprehensive Cancer Network. The act takes effect on April 1 following its enactment.

New York A06935 requires Medicaid to cover a wearable medical device for treating glioblastoma and other cancers.

New York A06935 amends the social services law to require Medicaid coverage for a wearable medical device that uses low-intensity, alternating electric fields to treat glioblastoma and other cancers. The coverage is based on medical and scientific evidence, including FDA approvals, Medicare coverage determinations, and clinical practice guidelines from organizations like the National Comprehensive Cancer Network. The act takes effect on April 1 following its enactment.